BioCentury | Feb 19, 2020
Finance

Eyeing IPO, Canbridge raises $98M to advance, commercialize products

Canbridge raised $98 million in a series D round to build out its commercial infrastructure in anticipation of two potential NDA approvals in mainland China this year. Canbridge also intends to solidify its rare disease...
BC Extra | Jan 16, 2020
Company News

Jan. 15 Company Quick Takes: Japan Tobacco gets rights to Dermavant therapy; plus Clovis, BMS, Recordati, BeiGene, Insilico-Pfizer, Novartis

Japan Tobacco gets Japanese rights to Dermavant’s dermatology therapy  Japan Tobacco Inc. (TOKYO:2914) licensed from Dermavant Sciences exclusive rights to develop and commercialize tapinarof in Japan for dermatology indications including psoriasis and atopic dermatitis. The...
BC Extra | Dec 13, 2019
Preclinical News

Dec. 12 Preclinical Quick Takes: POC for Aptose blood cancer candidate, plus Penn-Acorn AI, Neurimmune-Biogen and Syndax

Efficacy for Btk, FLT3 inhibitor in blood cancers  In a pair of posters at the American Society of Hematology (ASH) meeting in Orlando, Aptose Biosciences Inc. (NASDAQ:APTO; TSX:APS) and University of Texas MD Anderson Cancer...
BC Extra | Jul 10, 2019
Clinical News

Michael Becker, patient advocate and biotech exec, dies at 50

Michael Becker, a former biotech entrepreneur and author who became a fierce patient advocate in his final years, passed away from metastatic HPV-related cancer. He was 50. Becker was president, CEO, CFO and director for...
BC Extra | May 15, 2019
Company News

Management tracks: Biogen’s McKenzie departing for CSL; plus Rubius, SanBio, Avita and more

Paul McKenzie is leaving Biogen Inc. (NASDAQ:BIIB) as EVP, pharmaceutical operations & technology to become COO of CSL Ltd. (ASX:CSL). A veteran of Johnson & Johnson (NYSE:JNJ), Bristol-Myers Squibb Co. (NYSE:BMY) and Merck & Co....
BC Extra | Mar 14, 2019
Preclinical News

Antibody-drug conjugate against ALK could selectively treat neuroblastoma

Researchers from CHOP and Celldex showed that an antibody-drug conjugate targeting ALK selectively kills neuroblastoma cells, suggesting the ADC could have a better safety profile than marketed drug dinutuximab. Unituxin dinutuximab from United Therapeutics Corp....
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Extra | Dec 11, 2018
Company News

Management tracks: Grail, EUSA

Cancer detection company Grail Inc. (Menlo Park, Calif.) appointed Catherine Friedman chairman. She succeeds Bill Rastetter, who will continue as a director. Friedman joined Grail's board last year and also serves on the board of...
BC Week In Review | Nov 9, 2018
Clinical News

Aveo RCC compound trends toward detrimental survival effect, again

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) plans to submit an NDA to FDA for its renal cell carcinoma compound in about six months despite reporting preliminary data showing no overall survival benefit for Fotivda tivozanib as a...
BioCentury | Oct 6, 2018
Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
Items per page:
1 - 10 of 134
BioCentury | Feb 19, 2020
Finance

Eyeing IPO, Canbridge raises $98M to advance, commercialize products

Canbridge raised $98 million in a series D round to build out its commercial infrastructure in anticipation of two potential NDA approvals in mainland China this year. Canbridge also intends to solidify its rare disease...
BC Extra | Jan 16, 2020
Company News

Jan. 15 Company Quick Takes: Japan Tobacco gets rights to Dermavant therapy; plus Clovis, BMS, Recordati, BeiGene, Insilico-Pfizer, Novartis

Japan Tobacco gets Japanese rights to Dermavant’s dermatology therapy  Japan Tobacco Inc. (TOKYO:2914) licensed from Dermavant Sciences exclusive rights to develop and commercialize tapinarof in Japan for dermatology indications including psoriasis and atopic dermatitis. The...
BC Extra | Dec 13, 2019
Preclinical News

Dec. 12 Preclinical Quick Takes: POC for Aptose blood cancer candidate, plus Penn-Acorn AI, Neurimmune-Biogen and Syndax

Efficacy for Btk, FLT3 inhibitor in blood cancers  In a pair of posters at the American Society of Hematology (ASH) meeting in Orlando, Aptose Biosciences Inc. (NASDAQ:APTO; TSX:APS) and University of Texas MD Anderson Cancer...
BC Extra | Jul 10, 2019
Clinical News

Michael Becker, patient advocate and biotech exec, dies at 50

Michael Becker, a former biotech entrepreneur and author who became a fierce patient advocate in his final years, passed away from metastatic HPV-related cancer. He was 50. Becker was president, CEO, CFO and director for...
BC Extra | May 15, 2019
Company News

Management tracks: Biogen’s McKenzie departing for CSL; plus Rubius, SanBio, Avita and more

Paul McKenzie is leaving Biogen Inc. (NASDAQ:BIIB) as EVP, pharmaceutical operations & technology to become COO of CSL Ltd. (ASX:CSL). A veteran of Johnson & Johnson (NYSE:JNJ), Bristol-Myers Squibb Co. (NYSE:BMY) and Merck & Co....
BC Extra | Mar 14, 2019
Preclinical News

Antibody-drug conjugate against ALK could selectively treat neuroblastoma

Researchers from CHOP and Celldex showed that an antibody-drug conjugate targeting ALK selectively kills neuroblastoma cells, suggesting the ADC could have a better safety profile than marketed drug dinutuximab. Unituxin dinutuximab from United Therapeutics Corp....
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Extra | Dec 11, 2018
Company News

Management tracks: Grail, EUSA

Cancer detection company Grail Inc. (Menlo Park, Calif.) appointed Catherine Friedman chairman. She succeeds Bill Rastetter, who will continue as a director. Friedman joined Grail's board last year and also serves on the board of...
BC Week In Review | Nov 9, 2018
Clinical News

Aveo RCC compound trends toward detrimental survival effect, again

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) plans to submit an NDA to FDA for its renal cell carcinoma compound in about six months despite reporting preliminary data showing no overall survival benefit for Fotivda tivozanib as a...
BioCentury | Oct 6, 2018
Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
Items per page:
1 - 10 of 134